132 related articles for article (PubMed ID: 33890294)
41. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
42. Reduced expression of SRC family kinases decreases PI3K activity in NBS1-/- lymphoblasts.
Sagan D; Eckardt-Schupp F; Eichholtz-Wirth H
Biochem Biophys Res Commun; 2008 Dec; 377(1):181-6. PubMed ID: 18835245
[TBL] [Abstract][Full Text] [Related]
43. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
44. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
45. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
[TBL] [Abstract][Full Text] [Related]
46. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
[TBL] [Abstract][Full Text] [Related]
47. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
48. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.
Wortmann A; He Y; Christensen ME; Linn M; Lumley JW; Pollock PM; Waterhouse NJ; Hooper JD
J Biol Chem; 2011 Dec; 286(49):42303-42315. PubMed ID: 21994943
[TBL] [Abstract][Full Text] [Related]
49. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
50. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
[TBL] [Abstract][Full Text] [Related]
51. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Chang AY; Wang M
BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
[TBL] [Abstract][Full Text] [Related]
52. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Irwin ME; Bohin N; Boerner JL
Cancer Biol Ther; 2011 Oct; 12(8):718-26. PubMed ID: 21775822
[TBL] [Abstract][Full Text] [Related]
53. TRAF6 protein couples Toll-like receptor 4 signaling to Src family kinase activation and opening of paracellular pathway in human lung microvascular endothelia.
Liu A; Gong P; Hyun SW; Wang KZ; Cates EA; Perkins D; Bannerman DD; Puché AC; Toshchakov VY; Fang S; Auron PE; Vogel SN; Goldblum SE
J Biol Chem; 2012 May; 287(20):16132-45. PubMed ID: 22447928
[TBL] [Abstract][Full Text] [Related]
54. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
55. Multiplex analysis of Src family kinase signaling by microbead suspension arrays.
Campbell M; Lie WR; Zhao J; Hayes D; Mistry J; Kung HJ; Luciw PA; Khan IH
Assay Drug Dev Technol; 2010 Aug; 8(4):488-96. PubMed ID: 20482378
[TBL] [Abstract][Full Text] [Related]
56. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.
Koppikar P; Choi SH; Egloff AM; Cai Q; Suzuki S; Freilino M; Nozawa H; Thomas SM; Gooding WE; Siegfried JM; Grandis JR
Clin Cancer Res; 2008 Jul; 14(13):4284-91. PubMed ID: 18594011
[TBL] [Abstract][Full Text] [Related]
57. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
58. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation.
Leung EL; Wong JC; Johlfs MG; Tsang BK; Fiscus RR
Mol Cancer Res; 2010 Apr; 8(4):578-91. PubMed ID: 20371672
[TBL] [Abstract][Full Text] [Related]
59. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
60. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
